
A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2 amended as follows:

3 1. By amending subsection (f) to read:

4 "(f) Stimulants. Unless specifically excepted or unless
5 listed in another schedule, any material, compound, mixture, or
6 preparation which contains any quantity of the following
7 substances having a stimulant effect on the central nervous
8 system, including its salts, isomers, and salts of isomers:

9 (1) Aminorex;

10 (2) Cathinone;

11 (3) Fenethylamine;

12 (4) Methcathinone;

13 (5) N-ethylamphetamine;

14 (6) 4-methylaminorex;

15 (7) N,N-dimethylamphetamine; and

16 (8) Substituted cathinones, any compound, except bupropion
17 or compounds listed under a different schedule,



1 structurally derived from 2-aminopropan-1-one by
2 substitution at the 1-position with either phenyl,
3 naphthyl, or thiophene ring systems, whether or not
4 the compound is further modified in any of the
5 following ways:

6 (A) By substitution in the ring system to any extent
7 with alkyl, alkylendioxy, alkoxy, haloalkyl,
8 hydroxyl, or halide substituents, whether or not
9 further substituted in the ring system by one or
10 more other univalent substituents;

11 (B) By substitution at the 3-position with an acyclic
12 alkyl substituent; or

13 (C) By substitution at the 2-amino nitrogen atom with
14 alkyl, dialkyl, benzyl, or methoxybenzyl groups,
15 or by inclusion of the 2-amino nitrogen atom in a
16 cyclic structure.

17 Some other trade names: Mephedrone (2-methylamino-1-
18 p-tolylpropan-1-one), also known as 4-
19 methylmethcathinone (4-MMC), methylephedrone or MMCAT;
20 Methylenedioxypropylone (MDPV, MDPK); methylone or
21 3,4-methylenedioxymethcathinone; and 1-



1 (benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one,
 2 monohydrochloride, also known as Ethylone, bk-MDEA
 3 hydrochloride, MDEC; 3,4-Methylenedioxy-N-
 4 ethylcathinone; bk-Methylenedioxyethylamphetamine [-],
 5 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-
 6 pyrrolidinopropiophenone (4-MePPP); alpha-
 7 pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-
 8 benzodioxol-5-yl)-2-(methylamino)butan-1-one
 9 (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-
 10 1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-
 11 (methylamino)pentan-1-one (pentylone, bk-MBDP); 4-
 12 fluoro-N-methylcathinone (4-FMC, flephedrone); 3-
 13 fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-
 14 2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-
 15 pyrrolidinobutiophenone ([alpha]-PBP) and their
 16 optical, positional, and geometric isomers, salts, and
 17 salts of isomers, whenever the existence of such
 18 salts, isomers, and salts of isomers is possible."

19 2. By amending subsection (g) to read as follows:
 20 "(g) Any of the following cannabinoids, their salts,
 21 isomers, and salts of isomers, unless specifically excepted,



1 whenever the existence of these salts, isomers, and salts of
2 isomers is possible within the specific chemical designation:

- 3 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
4 naturally contained in a plant of the genus Cannabis
5 (cannabis plant), as well as synthetic equivalents of
6 the substances contained in the plant, or in the
7 resinous extractives of Cannabis, sp. or synthetic
8 substances, derivatives, and their isomers with
9 similar chemical structure and pharmacological
10 activity to those substances contained in the plant,
11 such as the following: Delta 1 cis or trans
12 tetrahydrocannabinol, and their optical isomers; Delta
13 6 cis or trans tetrahydrocannabinol, and their optical
14 isomers; and Delta 3,4 cis or trans-
15 tetrahydrocannabinol, and its optical isomers (since
16 nomenclature of these substances is not
17 internationally standardized, compounds of these
18 structures, regardless of numerical designation of
19 atomic positions, are covered);
- 20 (2) Naphthoylindoles; meaning any compound containing a 3-
21 (1-naphthoyl)indole structure with substitution at the



1 nitrogen atom of the indole ring by a alkyl,
2 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
4 morpholinyl)ethyl group, whether or not further
5 substituted in the indole ring to any extent and
6 whether or not substituted in the naphthyl ring to any
7 extent;

8 (3) Naphthylmethylindoles; meaning any compound containing
9 a 1H-indol-3-yl-(1-naphthyl) methane structure with
10 substitution at the nitrogen atom of the indole ring
11 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
12 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
13 2-(4-morpholinyl) ethyl group whether or not further
14 substituted in the indole ring to any extent and
15 whether or not substituted in the naphthyl ring to any
16 extent;

17 (4) Naphthoylpyrroles; meaning any compound containing a
18 3-(1-naphthoyl)pyrrole structure with substitution at
19 the nitrogen atom of the pyrrole ring by a alkyl,
20 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
21 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)



- 1 ethyl group whether or not further substituted in the
2 pyrrole ring to any extent, whether or not substituted
3 in the naphthyl ring to any extent;
- 4 (5) Naphthylmethylenes; meaning any compound containing
5 a naphthylideneindene structure with substitution at
6 the 3-position of the indene ring by a alkyl,
7 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
9 ethyl group whether or not further substituted in the
10 indene ring to any extent, whether or not substituted
11 in the naphthyl ring to any extent;
- 12 (6) Phenylacetylindoles; meaning any compound containing a
13 3-phenylacetylindole structure with substitution at
14 the nitrogen atom of the indole ring by a alkyl,
15 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
16 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
17 ethyl group whether or not further substituted in the
18 indole ring to any extent, whether or not substituted
19 in the phenyl ring to any extent;
- 20 (7) Cyclohexylphenols; meaning any compound containing a
21 2-(3-hydroxycyclohexyl) phenol structure with



- 1 substitution at the 5-position of the phenolic ring by
2 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
3 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
4 2-(4-morpholinyl) ethyl group whether or not
5 substituted in the cyclohexyl ring to any extent;
- 6 (8) Benzoylindoles; meaning any compound containing a 3-
7 (benzoyl) indole structure with substitution at the
8 nitrogen atom of the indole ring by a alkyl,
9 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
10 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
11 morpholinyl) ethyl group whether or not further
12 substituted in the indole ring to any extent and
13 whether or not substituted in the phenyl ring to any
14 extent;
- 15 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
16 pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
17 naphthalenylmethanone (another trade name is WIN
18 55,212-2);
- 19 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
20 methyloctan-2-yl)-6a,7,10,10a-



- 1 tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
2 HU-210/HU-211);
- 3 (11) Tetramethylcyclopropanoylindoles; meaning any compound
4 containing a 3-tetramethylcyclopropanoylindole
5 structure with substitution at the nitrogen atom of
6 the indole ring by an alkyl, haloalkyl, cyanoalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
8 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
9 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
10 morpholinyl)methyl, or tetrahydropyranylmethyl group,
11 whether or not further substituted in the indole ring
12 to any extent and whether or not substituted in the
13 tetramethylcyclopropyl ring to any extent;
- 14 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
15 its optical, positional, and geometric isomers, salts,
16 and salts of isomers (Other names: APINACA, AKB48);
- 17 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
18 optical, positional, and geometric isomers, salts, and
19 salts of isomers (Other names: PB-22; QUPIC);
- 20 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
21 carboxylate, its optical, positional, and geometric



- 1 isomers, salts, and salts of isomers (Other names: 5-
2 fluoro-PB-22; 5F-PB-22);
- 3 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
4 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
5 positional, and geometric isomers, salts, and salts of
6 isomers (Other names: AB-FUBINACA);
- 7 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
8 indazole-3-carboxamide, its optical, positional, and
9 geometric isomers, salts, and salts of isomers (Other
10 names: ADB-PINACA);
- 11 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
12 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its
13 optical, positional, and geometric isomers, salts, and
14 salts of isomers (Other names: AB-CHMINACA);
- 15 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
16 indazole-3-carboxamide, and geometric isomers, salts,
17 and salts of isomers (Other names: AB-PINACA);
- 18 (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
19 yl)methanone, and geometric isomers, salts, and salts
20 of isomers (Other names: THJ-2201);



- 1 (20) Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-
2 valinate, and geometric isomers, salts, and salts of
3 isomers (Other names: FUB-AMB);
- 4 (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
5 carboxamido)-3-methylbutanoate, and geometric isomers,
6 salts, and salts of isomers (Other names: 5-fluoro-
7 AMB, 5-fluoro-AMP);
- 8 (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
9 indazole-3-carboxamide, and geometric isomers, salts,
10 and salts of isomers (Other names: AKB48 N-(5-
11 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
12 analog, 5F-APINACA);
- 13 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
14 geometric isomers, salts, and salts of isomers (Other
15 names: STS-135, 5F-APICA; 5-fluoro-APICA);
- 16 (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
17 carboxylate, and geometric isomers, salts, and salts
18 of isomers (Other names: NM2201);
- 19 (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
20 (cyclohexylmethyl)-1H-indazole-3-carboxamide, and



1 geometric isomers, salts, and salts of isomers (Other
2 names: MAB-CHMINACA and ADB-CHMINACA); [and]

3 (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
4 carboxamido]-3,3-dimethylbutanoate (Other names: 5F-
5 ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
6 positional, and geometric isomers, salts, and salts of
7 isomers[-]; and

8 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
9 carboxamide (CUMYL-4CN-BINACA), its optical,
10 positional, and geometric isomers, salts, and salts of
11 isomers (Other names: SGT-78, 4-CN-CUMYL-BINACA,
12 CUMYL-CB-PINACA, CUMYL-CYBINACA, and 4-cyano CUMYL-
13 BUTINACA)."

14 SECTION 2. Section 329-16, Hawaii Revised Statutes, is
15 amended by amending subsection (g) to read as follows:

16 "(g) Hallucinogenic substances, unless listed in another
17 schedule, shall include:

- 18 (1) Nabilone[-]; and
- 19 (2) Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] in
20 an oral solution in a drug product approved for

1 marketing by the United States Food and Drug
2 Administration."

3 SECTION 3. Statutory material to be repealed is bracketed
4 and stricken. New statutory material is underscored.

5 SECTION 4. This Act shall take effect upon its approval.
6



Report Title:

Uniform Controlled Substances Act

Description:

Updates chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the federal Controlled Substances Act as required under section 329-11, Hawaii Revised Statutes. (SD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

